Picture of Bioventix logo

BVXP Bioventix News Story

0.000.00%
gb flag iconLast trade - 00:00
HealthcareAdventurousSmall CapContrarian

Director Dealing

RNS Number : 0767A

BioVentix PLC

13 April 2026

 

Bioventix plc 

 

("Bioventix" or "the Company") 

 

Director Dealing 

 

Bioventix plc (BVXP), a UK company specialising in the development and commercial supply of high-affinity monoclonal antibodies for applications in clinical diagnostics, announces that the Company was notified on 10 April 2026 that Ian Nicholson, Non-Executive Chairman, purchased a total of 1,000 ordinary shares of 5 pence each in the Company ("Ordinary Shares") at a price of 1,848 pence per Ordinary Share (the "Purchase").

 

Following the Purchase, Ian Nicholson has a beneficial interest in 14,500 Ordinary Shares, representing approximately 0.3 per cent. of the issued share capital of the Company. 

 

The notification below, made in accordance with the requirements of the EU Market Abuse Regulation, provides further details. 

 

 

For further information please contact: 

 

Bioventix plc
Peter Harrison
Chief Executive OfficerTel: 01252 728 001
Cavendish
Geoff Nash / Elysia Bough
Nigel Birks / Harriet Ward
Corporate Finance
ECM
Tel: 020 7220 0500
      Notification and public disclosure of transactions by persons discharging managerial responsibilities and persons closely associated with them     
1Details of the person discharging managerial responsibilities / person closely associated
a)NameIan Nicholson
2.Reason for the Notification
a)Position/statusNon-Executive Chairman
b)Initial notification/AmendmentInitial notification
3.Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
a)NameBioventix Plc
b)LEI213800225MHX7LZQY108
4.Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted
a)Description of the Financial instrument, type of instrumentOrdinary Shares of 5 pence each
Identification codeGB00B4QVDF07
b)Nature of the transactionPurchase of Ordinary Shares
c)Price(s) and volume(s)1,000 Ordinary Shares
1,848 pence
d)Aggregated information:
· Aggregated volume
· Price
Single transaction as in 4c) above
e)Date of the transaction10 April 2026
f)Place of the transactionLondon Stock Exchange, AIM Market (XLON)
    This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com. RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.   END     DSHEAELEFSAKEAA

Recent news on Bioventix

See all news